Cardiac glycosides

Cardiac glycosides' are a group of plant-derived substances that play an essential role in the treatment of heart failure. They are used when there is a need to strengthen the contractility of the failing heart in order to achieve sufficient cardiac output.

The main representative of this group is digoxin. Digitoxin, methyldigoxin, and strophanthin (oubain) were also formerly used.

Chemical structure
Molekula srdečních glykosidů sestává ze sterolového jádra, nenasyceného laktonového kruhu a z cukerné složky.

Mechanism of action
Cardiac glycosides have positive inotropic effects on cardiac muscle, they can increase myocardial contractility. The action of the drug starts at the cell membrane of the heart cell, where the drug has inhibitory effects on the sodium-potassium pump (Na+/K+-ATPase), which is responsible for the normal distribution of ions between the cell and the extracellular environment. As a consequence of a decrease in sodium pump activity, sodium cations accumulate inside the cell, causing an unfavourable gradient for Na+/Ca2+ changing pump, which normally pumps 3 sodium cations into the cell in exchange for 1 calcium cation. Due to increased intracellular sodium levels, the work of the Na+/Ca2+ changing pump and thus a rise in intracellular calcium. The inotropy is due to the concentration of intracellular calcium and therefore its intracellular rise will result in increased myocardial stiffness.

Cardiac glycosides also act indirectly to slow the heart rate by increasing the activity of the vagus nerve.

Effects

 * due to vagal irritation, heart rate is slowed'
 * slowing of conduction through the A-V node
 * positive inotropic effects on cardiac muscle, can increase myocardial contractility
 * increase baroreceptor sensitivity
 * increase left ventricular ejection fraction

Due to vagal irritation, digitalis glycosides have negative dromotropic and chronotropic effects. Traditionally, cardiac glycosides have been used to maintain control of atrial fibrillation.

Indication
Cardiac glycosides are most commonly given to patients with heart failure accompanied by atrial fibrillation or sine flutter.

Contraindication
Absolute:


 * hypertrophic obstructive cardiomyopathy
 * A-V block
 * hypokalemia
 * hypercalcemia
 * ventricular tachycardia
 * heart failure with slow sinus rhythm
 * sick-sinus syndrome
 * Wolff-Parkinson-White syndrome
 * carotid sinus hypersensitivity

Relative:


 * cor pulmonale
 * pulmonary embolism
 * acute myocardial infarction with sin. rhythm
 * mitral stenosis
 * constrictive pericarditis
 * acid-base imbalance
 * myocarditis

Dosing
For digoxin and other substances in this group, there is a very small margin between the therapeutic and toxic dose. Recommendations based on results from observational studies are that plasma concentrations should not exceed 2 ng/ml'. For a patient of normal weight and with sinus rhythm, a daily dose of 0.125 mg is appropriate. Digoxin is eliminated from the body by the kidneys and therefore a lower dose should be given in patients with renal insufficiency.

Common articles

 * Cardiotonics
 * Atrial Fibrillation
 * Atrial Flutter
 * Antiarrhythmics
 * Heart rhythm disorders

Extern links

 * Digoxin a EKG (TECHmED)
 * Intoxikácia digoxínom a EKG (TECHmED)

Použitá literatura





 * WIDIMSKÝ, Jiří. Srdeční selhání. 2. rozš. a přeprac. vyd vydání. Praha : Triton, 2003. 556 s.  ISBN 8072543857.


 * VÍTOVEC, Jiří a Jindřich ŠPINAR. Farmakoterapie kardiovaskulárních onemocnění. 1. vydání. Praha : Grada, 2000.  ISBN 8071695521.